Elon Musk’s Neuralink receives FDA green light for ‘first-in-human clinical study’
Business tycoon Elon Musk’s Neuralink announced that it has secured approval from the U.S. Food and Drug Administration to begin its “first-in-human clinical study.”
“We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study! This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people. Recruitment is not yet open for our clinical trial. We’ll announce more information on this soon!” the company tweeted.
“Congratulations Neuralink team!” Musk tweeted.
— Elon Musk (@Elon Musk)
Neuralink seeks to implant chips in people’s brains in a bid to help disabled people control computers with their mind, though the company also has additional long-term aspirations.
Neuralink’s stated mission is to “create a generalized brain interface to restore autonomy to those with unmet medical needs today and unlock human potential tomorrow.”
“Brain-computer interfaces have the potential to change lives for the better,” the company claims. “We are currently focused on giving people with quadriplegia the ability to control their computers and mobile devices with their thoughts,” Neuralink notes. “In the future, we hope to restore capabilities such as vision, motor function, and speech, and eventually expand how we experience the world.”
People who receive the implant would be able to charge it wirelessly.
“Our brain-computer interface is fully implantable, cosmetically invisible, and designed to let you control a computer or mobile device anywhere you go,” the company says. “The N1 Implant is powered by a small battery charged wirelessly from the outside via a compact, inductive charger that enables easy use from anywhere.”
Like Blaze News? Bypass the censors, sign up for our newsletters, and get stories like this direct to your inbox. Sign up here!
TheBlaze Read More
Leave a Reply